Cardiol Therapeutics (CRDL) to Release Quarterly Earnings on Tuesday

Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) is scheduled to announce its earnings results on Tuesday, March 26th.

Cardiol Therapeutics Trading Down 1.4 %

Cardiol Therapeutics stock traded down $0.02 during midday trading on Monday, hitting $1.46. The stock had a trading volume of 257,589 shares, compared to its average volume of 376,246. The stock has a market cap of $99.53 million, a P/E ratio of -4.42 and a beta of 1.00. Cardiol Therapeutics has a 12 month low of $0.45 and a 12 month high of $2.17. The business has a fifty day moving average price of $1.39 and a 200 day moving average price of $1.06.

Institutional Trading of Cardiol Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Tejara Capital Ltd acquired a new position in shares of Cardiol Therapeutics during the fourth quarter worth approximately $225,000. Vident Investment Advisory LLC boosted its position in shares of Cardiol Therapeutics by 139.6% during the first quarter. Vident Investment Advisory LLC now owns 126,157 shares of the company's stock worth $195,000 after buying an additional 73,512 shares during the period. Advisor Group Holdings Inc. boosted its position in shares of Cardiol Therapeutics by 2,240.7% during the first quarter. Advisor Group Holdings Inc. now owns 113,058 shares of the company's stock worth $173,000 after buying an additional 108,228 shares during the period. Osaic Holdings Inc. boosted its position in shares of Cardiol Therapeutics by 81.5% during the second quarter. Osaic Holdings Inc. now owns 66,800 shares of the company's stock worth $59,000 after buying an additional 30,000 shares during the period. Finally, Royal Bank of Canada lifted its position in Cardiol Therapeutics by 66.2% in the first quarter. Royal Bank of Canada now owns 35,214 shares of the company's stock worth $54,000 after purchasing an additional 14,020 shares during the period. 12.49% of the stock is owned by institutional investors.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis.